1. Home
  2. VHI vs MNPR Comparison

VHI vs MNPR Comparison

Compare VHI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VHI

Valhi Inc.

N/A

Current Price

$14.35

Market Cap

401.0M

Sector

Industrials

ML Signal

N/A

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$58.24

Market Cap

368.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHI
MNPR
Founded
1932
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
401.0M
368.9M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
VHI
MNPR
Price
$14.35
$58.24
Analyst Decision
Sell
Strong Buy
Analyst Count
1
11
Target Price
$12.00
$107.00
AVG Volume (30 Days)
9.0K
174.1K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
2.27%
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
$2,077,000,000.00
N/A
Revenue This Year
$33.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.44
$28.40
52 Week High
$20.00
$105.00

Technical Indicators

Market Signals
Indicator
VHI
MNPR
Relative Strength Index (RSI) 50.42 54.12
Support Level $13.57 $56.15
Resistance Level $14.44 $61.87
Average True Range (ATR) 0.46 3.84
MACD 0.03 0.39
Stochastic Oscillator 52.95 78.36

Price Performance

Historical Comparison
VHI
MNPR

About VHI Valhi Inc.

Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: